Mark Elliott Boulding, Executive VP AND CLO at PTC THERAPEUTICS, INC. (PTCT), sold 5,626 shares at $48.58 ($273K) on 2025-08-15, disclosed to the SEC on 2025-08-19.
Scheduled sale ($273k) by Executive VP AND CLO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $48.58 | 2,813 | $137K | 50.0% |
| 2 | $48.58 | 2,813 | $137K | 50.0% |
| Total | $48.58 avg | 5,626 | $273K | 100% |
| Filing → |
| PTCT | SELL | 2026-06-22 | $823K | — | Filing → |
| PTCT | SELL | 2026-05-19 | $203K | — | Filing → |
| PTCT | SELL | 2026-05-12 | $280K | — | Filing → |